Tracers / [90Y]Y-DOTA-DPhe1-Tyr3-octreotide

[90Y]Y-DOTA-DPhe1-Tyr3-octreotide

Also written as [Y-90]DOTA-DPhe1-Tyr3-octreotide; Y-90-DOTA-D-Phe1-Tyr3-octreotide; [Y-90]DOTA-D-Phe1-Tyr3-octreotide; Y-90-DOTA-D-Phe1-Tyr3-Octreotide

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 2

What it is

Compound class: Radiolabelled somatostatin analogue (DOTA-conjugated peptide)
Target / mechanism: Somatostatin receptor PMID 18349800
Clinical application: Neuroendocrine tumours (peptide receptor radionuclide therapy) PMID 18349800
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	—	10199941 1999 Eur J Nucl Med
—	—	—	—	—	[DOTA0,d-Phe1,Tyr3]octreotide	9096086 1997 Eur J Nucl Med

Need this precursor?We can point you to suppliers for [90Y]Y-DOTA-DPhe1-Tyr3-octreotide, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.